News & Events.

Arcuro Medical achieves two new milestones

CE marking in the EU and a new partnership with Genesis Biologics in the US

31 May 2020


Arcuro Medical has developed an all-suture, knotless meniscus repair system, the SuperBall, for an effective and secure repair. Arcuro’s proprietary SuperBall Meniscus Repair System consists of a knotless, all-suture anchor and innovative delivery system. The Company’s novel approach is based on a technique in which the entire procedure is performed inside the joint space using suture material only and requiring just one entry into the joint. Located in the knee joint, the delicate meniscus is a C-shaped cartilage that acts as a shock absorber and “cushions” the knee. Meniscus tears can be found in professional athletes, and as much as 60% of the population over age 65. To maintain functionality, current practice is moving away from surgical removal of the meniscus toward arthroscopic repair techniques. Worldwide, there are more than 2 million meniscus procedures performed annually. The global market (excluding China) is more than $300 million, with a CAGR of 13%.

The CE marking of the SuperBall Meniscus Repair System is an important milestone which will advance the commercialization of Arcuro’s technology throughout the European Union and open the way to access other key global markets. The partnership agreement with Genesis Biologics for the sales, marketing, and distribution of the SuperBall Meniscus Repair System is key to accelerating commercialization throughout the United States.

We at Genesis Biologics are excited about the unique opportunity to partner with Arcuro Medical. Arcuro Medical has developed a game changing product to help surgeons treat meniscal tears. In my 25 years of working in the orthopedic medical device arena, I have not experienced a more comprehensive, thought-out solution to address the critical need for effectively and reproducibly treating meniscal tears.

Genesis Biologics CEO Steve Bee

Arcuro Medical receives CE mark and reaches a partnership agreement with Genesis Biologics, a US company

See More News

19 December 2021

FruitSpec raises $5 million

FruitSpec’s Yield Management Platform provides digital visibility of fruit yield data to entire supply-chain production units

16 September 2020

Phytolon secures $4.1 million in funding

Funding for fermentation-based technology for the production of food colors

Skip to content